# Table of contents

* [ğŸ’Š The Decentralized FDA DAO](README.md)
* [ğŸ“˜ Historical Evidence Supporting Decentralized Efficacy Trials](historical-evidence-supporting-decentralized-efficacy-trials.md)
* [â˜  Problems We Seek To Address](constitution/1-introduction-and-challenges.md)
  * [ğŸ’° Clinical Research is Expensive](1-introduction-and-challenges/clinical-research-is-expensive.md)
  * [ğŸ¥¸ Trials Often Aren't Representative of Real Patients](1-introduction-and-challenges/trials-often-arent-representative-of-real-patients.md)
  * [â“ What We Don't Know](1-introduction-and-challenges/page-1.md)
  * [â± Deaths Due to US Regulatory "Drug Lag"](1-introduction-and-challenges/deaths-due-to-us-regulatory-drug-lag.md)
  * [ğŸ™ˆ Negative Results are Never Published](1-introduction-and-challenges/negative-results-are-never-published.md)
  * [ğŸ­ Conflicts of Interest](1-introduction-and-challenges/conflicts-of-interest.md)
  * [ğŸ—“ No Long-Term Outcome Data](1-introduction-and-challenges/no-long-term-outcome-data.md)
  * [ğŸ“ƒ Lack of Incentive to Discover the Full Range of Applications for Off-Patent Treatments](1-introduction-and-challenges/lack-of-incentive-to-discover-the-full-range-of-applications-for-off-patent-treatments.md)
  * [ğŸ¥« No Data on Unpatentable Molecules](1-introduction-and-challenges/no-data-on-unpatentable-molecules.md)
  * [ğŸ¤’ People With Rare Disease are Severely Punished](1-introduction-and-challenges/people-with-rare-disease-are-severely-punished.md)
  * [ğŸ”® Pre-Determining Clinical Endpoints Requires Psychic Powers](pre-determining-clinical-endpoints-requires-psychic-powers.md)
* [ğŸª™ Tokenomics](constitution/6-tokenomics.md)
* [ğŸ“ˆ Impact of Innovative Medicines on Life Expectancy](impact-of-innovative-medicines-on-life-expectancy.md)
* [ğŸ¯ Goals](constitution/2-solution.md)
  * [ğŸ­ More Cures and Less Lifelong Attempts at Masking Symptoms](more-cures-and-less-lifelong-attempts-at-masking-symptoms.md)
  * [ğŸ§ Greater Competitive Innovation and Fewer Monopolies](greater-competitive-innovation-and-fewer-monopolies.md)
  * [ğŸ‘€ Lower Costs of Validated Observational Research for Efficacy](lower-costs-of-validated-observational-research-for-efficacy.md)
  * [ğŸŒ Cost Savings from Decentralized Clinical Trials](cost-savings-from-decentralized-clinical-trials.md)
* [ğŸ“– References](constitution/12-references.md)
